Loading
A phase 1 trial of [Ac-225]RTX-2358 run by Ratio Therapeutics, Inc., now recruiting.
Actinium Therapy for Late-stage Aggressive Sarcomas is a phase 1 interventional study registered as NCT07156565 by Ratio Therapeutics, Inc., with 48 participants planned, started 2025-11-12. Conditions recorded: Advanced Soft Tissue Sarcoma. Interventions recorded: [Ac 225]RTX-2358 and [Cu64]LNTH-1363S.
Shares [Ac-225]RTX-2358, Ratio Therapeutics and the tag pipeline.
Shares Soft tissue sarcoma of the extremity (localised and advanced) and the tag pipeline.
Shares [Ac-225]RTX-2358, Ratio Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/